Case Studies: Page 1 > Page 2 >
Clearing the way to market
We were approached by a pharmaceutical company that was planning to sell one of its proprietary drugs in a newly designed package which provided a controlled release of the drug to a patient.
The company had become aware of a European patent recently granted to one of its competitors with broad patent claims that covered the release mechanism. We filed an opposition to the European patent at the European Patent Office on the basis that the claims of the patent were too broad. We found a research paper published by a University professor which showed that the broad idea of the release mechanism was already known and used this to force the patent claims to be narrowed, so that the patent would not be infringed by our client.
Our People
News
- Venner Shipley is now the preferred IP firm of the Oxbridge Biotech Roundtable (OBR)
- “Swiss” Claims Under the Microscope: AstraZeneca v Ranbaxy
- Brüstle v Greenpeace – The Patentability of Stem Cells in Europe
- Apotex Inc. v Les Laboratoires Servier
- The UK Court of Appeal Gives Guidance on Sufficiency: Novartis AG and Cibavision AG v Johnson & Johnson
Downloads

